News

1 2 3 4 5 10 14 18
NEWS

SOTIO Secures €280m of Funding to Expand and Advance Clinical Pipeline

  • PPF Group provides funding to advance SOTIO through key clinical milestones
  • Proceeds shall be used to conduct two phase 2 studies with SOT101, including a checkpoint inhibitor combination trial
  • Three programs (SOT102, BOXR1030, and SOT201) to advance through phase 1

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that is has secured €280m of funding to significantly expand and advance its clinical pipeline, including its lead asset SOT101, an IL-15 superagonist, and three new clinical programs until end of 2023.

NEWS

SOTIO Strengthens its Strategic Advisory Board with Esteemed Oncology Experts and Industry Veterans

SOTIO Biotech, a clinical stage immune-oncology company owned by PPF Group, announced the addition of three world-renowned clinical oncology research experts and biotechnology business development and commercialization veterans to its strategic advisory board. New members of the Strategic Advisory Board include Alise Reicin, M.D., Josep Tabernero, M.D., Ph.D. and Anthony Tolcher, M.D., FRCPS(C).

NEWS

SOTIO Expands its Antibody-Drug Conjugate Pipeline with Exclusive Collaboration and License Agreement with LegoChem Biosciences

  • SOTIO Biotech licenses LegoChem Biosciences (LCB) technology for five new antibody-drug conjugate (ADC) programs
  • Rights to LCB’s ADC platform acquired for total of up to $1027.5 million payable based on certain developments and regulatory achievements, including upfront and near-term success dependent milestones worth up to $29.5 million
  • SOTIO will be responsible for the research, development, manufacturing and commercialization of the ADC products

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, today announced an exclusive, target-specific license and option agreement with LegoChem Biosciences Inc. (LCB, KOSDAQ: 141080), a biotechnology company focused on developing its clinical-stage platform technology enabling antibody-drug conjugates (ADCs) with an excellent therapeutic index. SOTIO will obtain rights to deploy LCB’s ADC technology for up to five therapeutic programs targeting distinct tumor-associated antigens.